McAndrew, Nicholas P. http://orcid.org/0000-0002-6799-5204
Dickson, Mark A.
Clark, Amy S.
Troxel, Andrea B.
O’Hara, Mark H.
Colameco, Christopher
Gallager, Maryann
Gramlich, Kristi
Zafman, Kelly
Vaughn, David
Schwartz, Gary K.
O’Dwyer, Peter J.
DeMichele, Angela
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA008748, P01CA047179, P50CA140146)
Pfizer Research Grant
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Penn-Pfizer Alliance
Article History
Received: 11 July 2019
Revised: 13 May 2020
Accepted: 18 June 2020
First Online: 9 July 2020
Ethics approval and consent to participate
: Each of the clinical trials in this study, including the informed consent forms authorising patient agreement and participation in each study, were approved by their respective institutional review boards of the University of Pennsylvania and Memorial Sloan Kettering Cancer Center and performed in accordance with the Declaration of Helsinki.
: The data analysed in this study are securely managed by the study team and not available as part of a public database but can be made available in a deidentified fashion if requested by the editorial board.
: N.P.M. received research funding from Novartis and Daiichi Sankyo; advisory board honorarium from Novartis, Daiichi Sankyo, and Genomic Health; consulting honorarium from Daiichi Sankyo and Novartis; travel accommodation from TRIO, Daiichi Sankyo, and Roche, as well as speaking honorarium from Novartis. M.A.D. has received research funding from Pfizer, Eli-Lilly, and AADi, along with providing consultation and advisory to Pfizer and Celgene. A.S.C. has received research funding from Novartis. D.V. received research funding from Merck, Astellas, and Genetech, along with providing consultation and sitting on the advisory board to Merck. M.H.O. received research support from Eli Lilly, BMS, and Celldex and received Honoraria from Astra Zeneca, along with providing consultation to Karyopharm and Exelixis. P.J.O. has received research funding from Amgen, Bayer, BBI Healthcare, Bristol-Myers Squibb, Celgene, Five Prime Therapeutics, Forty Seven, Genentech, GlaxoSmithKline, Merck, Mirati Therapeutics, Novartis, Pfizer, and Pharmacyclics, along with providing consultation and advising to Bristol-Myers Squibb, Five Prime Therapeutics, Forty Seven, and Genentech. A.D. has received research funding from Novartis, Pfizer, Genentech, Calithera, and Menarini, along with providing consultation to Contact Therapeutics, Pfizer, Novartis, and Calithera. All remaining authors have declared no conflict of interests.
: This work was supported by the NIH [grant number T32-CA-09679 to N.P.M.] and the NCI at NIH [grant numbers P01CA047179 and P50CA140146 to G.K.S; grant number P30CA008748 to M.A.D.]. The authors acknowledge the additional following funds, companies, and grants that contributed to this research: the Penn–Pfizer Alliance (to A.D. and P.J.O.) and Pfizer (research support to M.A.D.).